105 results
Page 5 of 6
424B3
3njoukdb
10 Apr 15
Prospectus supplement
12:00am
10-K
5apth48
25 Mar 15
Annual report
12:00am
424B3
1xvm2thj dhp
26 Feb 15
Prospectus supplement
12:00am
8-K
EX-99.1
bsgoah pgucylesvm
5 Feb 15
Recro Pharma to Present at the 17th Annual BIO CEO & Investor
12:00am
8-K
EX-99.1
dog6n chw6ia
3 Feb 15
Recro Pharma Enters into Common Stock Purchase Agreement with Aspire Capital
12:00am
8-K
1enpk8wxx809nxluplv
19 Dec 14
Departure of Directors or Certain Officers
12:00am
8-K
EX-99.1
6y15g eoggzuajhb
10 Nov 14
Recro Pharma Reports Third Quarter 2014 Financial Results
12:00am
8-K
EX-99.2
f9ie6p
10 Nov 14
Recro Pharma Reports Third Quarter 2014 Financial Results
12:00am
8-K
EX-99.1
gt559
30 Oct 14
Recro Pharma Announces Dosing of First Patient in Phase II REC-14-013 Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery
12:00am
8-K
EX-99.1
08fdwit45a
9 Sep 14
Recro Pharma to Present at the 2014 Aegis Healthcare & Technology Conference
12:00am
8-K
EX-99.2
miwtl2vauaogr
9 Sep 14
Recro Pharma to Present at the 2014 Aegis Healthcare & Technology Conference
12:00am
8-K
ef8uq8gzxh mhu2j
4 Sep 14
Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN
12:00am
8-K
EX-99.1
k8vf71o62 g9leqxso
4 Sep 14
Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN
12:00am
8-K
EX-99.1
jawo3r31lwwxaoi
12 Aug 14
Recro Pharma Reports Second Quarter 2014 Financial Results
12:00am
8-K
EX-99.1
fn2sxywn indi
1 Jul 14
Other Events
12:00am
8-K
EX-99.1
mcsey8bsns
17 Jun 14
Recro Pharma Announces Dosing of First Patient in Phase IIb Clinical Trial of Dex-IN for Treatment of Acute Pain Following Surgery
12:00am
8-K
EX-99.1
uey7e
1 Apr 14
This presentation includes forward-looking statements within the meaning of Section
12:00am
8-K
EX-99.1
r1yeasl9if6 u39imqp
13 Mar 14
Recro Pharma Announces New Board Members
12:00am